Zydus Lifesciences Limited

Stocks

Delayed NSE India S.E. Other stock markets 03:26:16 2026-07-14 am EDT			5-day change	1st Jan Change
1,141.90 ^INR	+0.94%		-0.98%	+24.86%

Jul. 10	India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears	RE
Jul. 03	Zydus Signs MoU with Apollo Hospitals to Offer Guardant Health?s Shield Multi-Cancer Detection Test in India	CI

Published on 05/19/2026 at 09:20 am EDT - Modified on 05/19/2026 at 02:35 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, good day, and welcome to Zydus Lifesciences Earnings Conference Call for the Fourth Quarter FY '26. [Operator Instructions]

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Jul. 10	India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears	RE
Jul. 03	Zydus Signs MoU with Apollo Hospitals to Offer Guardant Health?s Shield Multi-Cancer Detection Test in India	CI
Jul. 03	Zydus Lifesciences Signs MoU With Apollo Hospitals for Multi-Cancer Detection Test; Shares Up 3%	MT
Jun. 26	Zydus Sunshine announced that it expects to receive $5 million in funding from Zydus Lifesciences Limited	CI
Jun. 26	Zydus Lifesciences to Form 50:50 JV With Sunshine Healthcare in Sri Lanka	MT
Jun. 25	Zydus Lifesciences Limited and Sunshine Healthcare Lanka Limited Enter Joint Venture to Establish Zydus Sunshine Lifesciences Private Limited with Investment Commitment	CI
Jun. 16	Zydus Lifesciences Completes Acquisition of US-Based Assertio Holdings	MT
Jun. 16	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
Jun. 10	Zydus Lifesciences Unit Secures Reduction in GST Tax Demands	MT
Jun. 09	Zydus Lifesciences Limited's Equity Buyback announced on May 19, 2026, has expired.	CI
Jun. 08	Zydus Lifesciences Limited Receives Warning Letter from U.S. Food and Drug Administration	CI
Jun. 03	Zydus Lifesciences Receives USFDA Warning Letter for Baddi Facility	MT
May. 28	Zydus Lifesciences says US FDA grants priority review to Zydus Therapeutics' NDA for saroglitazar to treat pbc	RE
May. 27	Zydus Lifesciences share buyback price increased from 1,150 rupees per share to 1,260 rupees per share	RE
May. 20	Zydus Lifesciences to Seek Acquisitions in Specialty and Rare Disease Segments	CI